



cancers



an Open Access Journal by MDPI

Advanced Cancer Nanotheranostics

Guest Editor:

Prof. Dr. Marco Filice

Nanobiotechnology for Life Sciences Group, Department of Chemistry in Pharmaceutical Sciences, Faculty of Pharmacy, Universidad Complutense de Madrid (UCM), Plaza Ramón y Cajal s/n, E-28040 Madrid, Spain

Deadline for manuscript submissions:

closed (20 October 2023)

Message from the Guest Editor

Dear Colleagues,

Cancer is still a leading cause of death worldwide. In recent decades, nanotechnology has promoted the production of a wide set of nanoplatforms with multifunctional abilities for tumor targeting, drug loading, and controlled release. Furthermore, imaging functionalities have been coupled to these nanoplatforms, thus enabling the possibility to also diagnose cancer and monitor therapeutic progression non-invasively and in real time. Such a fusion of therapy and diagnosis promoted by nanostructured materials is known as ‘nanotheranostics’, and these multifunctional nanotools have encountered a great applicability in biomedicine and especially in the medical management of a lot of cancers.

This Special Issue will highlight the current state of the art in the exciting and highly promising area of cancer nanotheranosis.



mdpi.com/si/92306

Special Issue



cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI